On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options
Continue Reading Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million
On September 13, 2021, Regenxbio, a Maryland biotech company, and AbbVie announced that they have entered an agreement to develop
Continue Reading Abbvie and Regenexbio Agree to Develop and Commercialize Eye Disease Gene Therapy
Following the successful development (and financial success) of its mRNA vaccine, biotech company Moderna is now looking to expand into
Continue Reading Moderna’s Next Steps: Spikevax Today, Gene Editing Tomorrow
Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the
Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
On July 15, 2021, American Gene Technologies (AGT), a Maryland biotech company, announced that the safety data in its Phase
Continue Reading American Gene Technologies Celebrates Milestone in HIV Cure Development
On July 27, 2021, Amgen announced that it will acquire Bay area-based Teneobio, a privately held, clinical stage biotechnology
Continue Reading Amgen Acquires Multispecific Immunotherapy Biotech Startup TeneoBio
mRNA pioneer BioNTech announced recently that it is developing an mRNA-based vaccine to attempt to eradicate malaria. Its efforts are
On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode
Continue Reading Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform
Dual-use ventures—startups that intend to sell both commercially and to the Department of Defense (DoD)—enjoy many advantages. You have a
Continue Reading Dual-Use Ventures & Intellectual Property: SBIR Data Rights, Patents, and Deals
In today’s world, e-commerce and online visibility are sine qua non for success. Businesses are willing to invest considerable sums
Continue Reading Domain Name “Trolls”: The Trademark Trial and Appeal Board May Have Offered A Way Out